NBIX Logo

Neurocrine Biosciences, Inc. (NBIX) 

NASDAQ
Market Cap
$12.71B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
633 of 776
Rank in Industry
37 of 47

Largest Insider Buys in Sector

NBIX Stock Price History Chart

NBIX Stock Performance

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA …

Insider Activity of Neurocrine Biosciences, Inc.

Over the last 12 months, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $114.86M worth of Neurocrine Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $51.81M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 59,000 shares for transaction amount of $351,345 was made by BVF PARTNERS L P/IL (10 percent owner) on 2011‑10‑12.

List of Insider Buy and Sell Transactions, Neurocrine Biosciences, Inc.

2024-10-03SaleChief Corp. Affairs Officer
1,295
0.0013%
$113.66$147,190+4.19%
2024-09-13SaleChief Corp. Affairs Officer
3,461
0.0034%
$121.88$421,828-4.33%
2024-08-15Saledirector
14,250
0.0141%
$146.69$2.09M0.00%
2024-08-13Saledirector
11,570
0.0117%
$150.43$1.74M0.00%
2024-08-13SaleChief Financial Officer
14,100
0.0143%
$150.38$2.12M0.00%
2024-08-13SaleChief Regulatory Officer
7,143
0.0072%
$150.10$1.07M0.00%
2024-08-06SaleChief Regulatory Officer
273
0.0003%
$147.70$40,322-17.26%
2024-08-01SaleChief Legal Officer
2,996
0.003%
$154.01$461,423-21.23%
2024-08-01SaleChief Human Resources Officer
12,632
0.0126%
$153.26$1.94M-21.23%
2024-07-16Saledirector
930
0.001%
$150.03$139,530-17.09%
2024-07-16SaleChief Legal Officer
7,004
0.0077%
$150.00$1.05M-17.09%
2024-07-16SaleChief Financial Officer
900
0.001%
$150.04$135,037-17.09%
2024-07-16SaleChief Human Resources Officer
900
0.001%
$150.04$135,036-17.09%
2024-07-16SaleChief Regulatory Officer
2,857
0.0031%
$150.03$428,627-17.09%
2024-07-01SaleChief Human Resources Officer
10,000
0.0103%
$140.19$1.4M0.00%
2024-07-01SaleChief Regulatory Officer
272
0.0003%
$138.11$37,5660.00%
2024-05-31SaleChief Regulatory Officer
273
0.0003%
$136.55$37,278-3.37%
2024-05-29Saledirector
40,000
0.0394%
$133.46$5.34M-1.15%
2024-05-17Saledirector
2,100
0.0021%
$141.84$297,860-6.10%
2024-05-17Saledirector
1,106
0.0011%
$141.90$156,943-6.10%

Insider Historical Profitability

<0.0001%
BVF PARTNERS L P/IL10 percent owner
3527700
3.4843%
$125.583610<0.0001%
MITCHELL W THOMASdirector
1000
0.001%
$125.5827+29.05%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$1.9B13.6713.76M+0.83%+$15.6M0.04
The Vanguard Group$1.37B9.879.93M+2.27%+$30.42M0.03
State Street$550.3M3.973.99M-1.81%-$10.12M0.02
JPMorgan Chase$316.54M2.282.3M+32.24%+$77.18M0.03
Renaissance Technologies$310.55M2.242.25M+13.23%+$36.29M0.49
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.